Welcome to another top-notch post from your stock friend Otcstockz.com. Here in this article, we will talk about Xcelerate, Inc. (OTC: XCRT), a top Healthcare Services stock to watch. If you like this post then please do share it with your investor friends and give us 5 stars rating. Please comment to keep us grounded.
Summary on how Xcelerate, Inc. (OTC: XCRT Stock) is becoming top Healthcare Services stock to watch
- Under the company’s CEO and Director Mike O’Shea’s inspiring leadership, Xcelerate Inc (OTCQB:XCRT) has accomplished a number of significant milestones since June 2021.
- They built a fully functional corporate website that displays the company’s ongoing development and updates.
- They attained Pink current reporting status with OTC Markets. They also started trading under the current ticker symbol XCRT. Recently they achieved OTCQB status.
- By October 2022, Xcelerate had accomplished significant milestones, including buying a 51% membership interest in AfiyaSasa Africa, LLC, starting the AfiyaSasa Africa Pilot Project in Four African Hospitals.
- Xcelerate has also purchased a portfolio of licensed and patented intellectual property. According to Xcelerate’s most recent release, they have significantly increased their patent portfolio and obtained patent protection in nine additional countries, including the EU, Russia, and Korea.
Technology became paramount in top healthcare services
Globally, telemedicine became essential in March 2020, as we faced the uncertainty of a Coronavirus pandemic. As telehealth and telemedicine programs became the top level of advertising almost overnight, technology became paramount in healthcare. It’s true that we’ve been relatively fortunate with this transition, but thousands of villages around the world have lived for decades without basic medical equipment, qualified healthcare professionals or sanitation facilities.
“The problem is particularly acute in Africa”
Tanzania currently has one doctor per 20,000 patients, according to the World Health Organization. Sierra Leone has three physicians for every 100,000 people. And according to GlobalVoices.org, “ At the peak of COVID-19 in 2020, the Central African Republic, a country of about 5 million people, had just 3 ventilators.”
In this area, Xcelerate, Inc. (XCRT Stock) is stepping up to show the significance of technology in top healthcare services.
Using artificial intelligence (AI), augmented reality (AR), the Internet of Things (IOT) and wearable technologies, this startup assists patients in remote villages or areas where healthcare services is difficult to access. The business offers a way for patients and their doctors to get over travel and distance barriers and gives them the straightforward tools and solutions required to undertake medical diagnostics testing wherever they are.
Xcelerate (Ticker Symbol: XCRT) is a small-cap company that has been in operation for a long time but has become very active in the past year. The company has been able to acquire a number of high-quality patents for its proprietary technologies and has signed a number of contracts with major companies. In this article we will discuss what makes Xcelerate so appealing from an investment perspective and why we believe it could be worth much more than its current price tag.
Xcelerate (XCRT Stock) has a very strong business plan and they are doing everything they can to make sure their company is successful. Per OTCmarkets.com, Xcelerate Inc has assembled an internationally recognized team of translational clinicians, engineers and business leaders including a Nobel laureate in Medicine, a world renowned neurosurgeon and a PhD in physics, to identify, acquire, and develop engineering advancements, intellectual property and operating business in, or with applications in medical technology and clinical care. Xcelerate (XCRT) acquires innovation at the engineering / patent level, marries it with appropriate early-stage operational med tech companies and applies it in a controlled clinical care setting which fosters engineering/clinical/business advancements under one umbrella.
The company’s CEO and Director, Mike O’Shea, has a very strategic vision for it. In June 2021, Xcelerate appointed BF Borgers CPA PC as the business’s independent accountant to audit its financial statements as part of his overall strategy. The hiring of the auditing firm, he said is “another step in the company’s plan to bring value to its shareholders”, He went on to describe his strategy as a long-term process and initiative to eventually up-list to OTCQB and national exchange.
Under Mike O’Shea’s inspiring leadership, Xcelerate has accomplished a number of significant milestones since June 2021. They built a corporate website at Xcelerate Inc (Ticker symbol:XCRT) that displays the company’s ongoing development and updates, and they attained reporting status with OTC Markets. They also started trading under the current ticker symbol, XCRT.
By October 2022, Xcelerate had accomplished significant milestones, including buying a 51% membership interest in AfiyaSasa Africa, LLC, starting the AfiyaSasa Africa Pilot Project in Four African Hospitals, and being uplisted as an OTCQB firm. Xcelerate has also purchased a portfolio of licensed and patented intellectual property from HS Pharmaceutical as anticipated in 2021. According to Xcelerate’s most recent release, they have significantly increased their patent portfolio and obtained patent protection in nine additional countries, including the EU, Russia, and Korea.
Below, we’ll provide a quick explanation of Xcelerate Incorporate’s patent portfolio, AfyaSasa Africa initiative, and competent advisory board.
What is AfiyaSasa Africa?
AfiyaSasa Africa, LLC (ASA) is a start-up medical technology and virtual health company founded by Tanzanian world-renowned Neurosurgeon Dilan Ellegala. It helps patients in developing countries meet their medical needs by interacting with physicians through its platform.
The ASA platform incorporates artificial intelligence (AI) and (Augmented Reality) AR developed by AdviNOW to connect individuals living in remote & urban areas with limited medical infrastructure and few medical professionals. The system is accessed by patients on their cell phones, tablets, or computers, and allows licensed physicians and other medical personnel to conduct initial check-in, triage, and determine the most appropriate care path, virtually. The system is equipped with facial recognition and storage capability to ascertain if the patient is a return patient.
Additionally, through a set of questions and answers that are dynamically integrated with the systems proprietary AI component, measurements may be taken with medical devices that connect to a cell phone, tablet or computer (i.e. stethoscope, thermometer, pulse oximeter etc.), bringing the telemedicine virtual appointment to the next level and beyond.
The AfiyaSasa Tanzania Project introduced at 4 hospitals around the nation under the moniker of its now wholly-owned subsidiary, with each offering a unique set of services and telehealth capabilities, including:
- NSK Hospitals and the
- Kilimanjaro Christian Medical Center (KCMC)
- Haydon Lutheran Hospital
- Arusha Lutheran Medical Center (ALMC)
Jakaya Kikwete Cardiac Institute, a fifth hospital, has expressed a genuine interest in taking part in the pilot program, therefore a potential program there is currently in the works.
When you consider that Tanzania has a population of close to 60.8 million people, many of whom are in urgent need of medical care, the program’s initial reach would represent a total catchment area of almost 20 million prospective patients.
The company will continue implementing similar projects at hospitals and outreach clinics throughout Tanzania and other countries in Africa once the pilot program has been built, tested, and widely accepted by both patients and medical professionals.
By the end of Q4 2022, Xcelerate anticipates that its fully operational beta sites will be successful, and anticipates that income will start to flow in early 2023.
Patent Filed & acquired by Xcelerate Inc (OTC: XCRT)
The portfolio consists of four issued and one pending U.S. patents, two issued and one pending European patent, as well as certain licensing agreements in conjunction with research developed by Cambridge University.
- U.S. 9,889,151: methods of treating specific cancers with a composition releasing orthosilicic acid in vivo
- U.S. 9,333,224: methods of treating bacterial infection with a composition releasing orthosilicic acid in vivo
- U.S. 10,493,097: methods of treating specific types of ulcers (wounds) with a composition releasing orthosilicic acid in vivo
- U.S. 16/089,613: composition for bone repair/replacement comprising silicate and bone/bone surrogate
- U.S. 16/670,060 pending
European Patents – Validated in Germany, Spain, France, the United Kingdom, Ireland, Italy
- EP 2211868: Silicate solution for treating melanoma
- EP 3305305: Silicate solution for wound healing
- EP 21178277.6 pending
- In-licensed IP (United Kingdom Research and Innovation)
- Granted U.S., EP, AU, JP, Eurasian, CN patents
- Pending in CA, HK, KR, SG
Strong Management Team of XCRT Stock
The long-term success of every organization depends on having “best in class” management. The explanation is straightforward: Management is in charge of the conception, development, and pace of expansion of all other value drivers. Good management is necessary for a variety of factors, including customer diversification, a tried-and-true growth strategy, sustainable revenue, enhancing cash flow, competitive advantage, and financial controls. A top-notch management team generates transferrable value more efficiently than any other value driver.
The management team consists of CEO and Director Mike O’Shea, a certified financial investigator and forensic accountant with extensive experience with organizations including the US Secret Service, ATF, FBI, Resolution Trust Corporation, Office of the Controller of the Currency, and Federal Deposit Insurance Corporation. Director, Jason Householder is the Co-Founder and CEO of Charlotte based LenDRgroup Consulting, has more than a decade of experience in the healthcare banking field and specializes in assisting medical, dental, and veterinary practices to devise strategies that run their businesses effectively. Another Director, Steve Gravely is the President of the Consulting Group of Jocassee, Inc, has been responsible for the start-up of 25 manufacturing plants around the world and over 300 new product introductions for large corporations such as Michelin, AT&T, NCR, Fluor/Maruti (India), and General Motors.
Read more about the Management team
Strong Advisory board
An advisory board is a group that offers management of a company, group, or foundation non-binding strategic counsel. Compared to a board of directors, an advisory board has more flexibility in terms of structure and management due to its informal character. Instead of making judgments, an advisory board’s function is to strengthen the confidence of the decision-makers who speak for the organization by offering up-to-date information, critical analysis, research and opinion. Xcelerate Inc. has put together a group of translational physicians, engineers, and business leaders of high standing.
Xcelerate Inc.’s advisory board includes renowned medical Nobel laureate Dr. Barry Marshall, well-known neurosurgeon Dr. Dilan B. Ellegala, and a research scholar with a Phd in X Ray & Material Physics Dr. Anja Glisovic. The advisory board recently welcomed Cathy Scangarella, Chief Business Development Officer and Sector Lead for the Life Sciences at Choose New Jersey.
Read more about the Advisory Board
Future is bright and promising
Mike O’Shea, the organization’s CEO and director, outlines his strategic strategy in one of the in-depth interview by Proactive
AI is already at work enhancing convenience and efficiency, lowering costs and errors, and generally making it simpler for more patients to access the healthcare they require. Examples include patient self-service, chat bots, computer-aided detection (CAD) systems for diagnosis, and image data analysis to identify candidate molecules in drug discovery. The goal of Xcelerate is to increase public access to doctors and healthcare through the application of AI. Xcelerate is distinctive in that it was created with the goal of bridging the gap between early developments in non-medical engineering and intellectual property and their application to clinical care.
Just as expected, Xcelerate upgraded their listing and switched from the OTC Pink Markets to the OTCQB, with an eye toward the Nasdaq in the near future. Nearly all of Xcelerate’s operating costs are covered by revenue, and the company is currently debt-free. Xcelerate expects its fully operational beta sites to be successful by the end of Q4 2022 and forecasts that revenue will start to flow in early 2023.
Disclaimer: We are not liable for any stock losses, therefore please invest at your own risk. Thank you for taking the time to read our content.
Make sure you are a subscriber to otcstockz since we will update on Xcelerate, Inc. (XCRT Stock) as new information becomes available.
Read how to buy Penny Stocks : Buying Penny Stocks for Less Than $1? What You Must Understand
Read how to buy Penny Stocks :How to purchase OTC Stocks in 2022?